- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03393338
Diabetes Interprofessional Team to Enhance Adherence to Medical Care (DM I-TEAM)
Přehled studie
Detailní popis
AAs have twice the rate of DM as Whites, and worse glycemic control, less optimal medication regimens, and less trust in the medical system. These disparities contribute to why AAs with DM are more likely to go blind, lose limbs, require dialysis, develop dementia, and die than Whites. These disparities, in turn, reflect racial differences in education, income, health literacy, cultural beliefs, experiences of discrimination, and social adversity, which can lead to: 1) poor glycemic control; 2) suboptimal medication use; and 3) mistrust in medical care. DM I-TEAM addresses these 3 factors, which often precipitate ED and hospital care, using a culturally relevant, multidisciplinary team treatment approach to reduce the need for high acuity medical care, and equip underserved AAs with DM with the knowledge and skill to gain the benefits of high quality medical care that is otherwise available to everyone. Our approach applies currently available treatment elements in a culturally-relevant way to create a more equitable health landscape. Our immediate goal is to engage a high-risk population in treatment that can be trusted; that recognizes the realities of their lives (e.g., financial insecurity); that improves the quality of the medication they take, and that builds their self-efficacy to manage DM. The intermediate goal is to prevent untoward medical events that necessitate ED or hospital care. The long-term goal is to reverse the pernicious racial disparities that now characterize healthcare in the U.S. DM I-TEAM can achieve these goals by getting the right care to the right patient at the right time. DM I-TEAM is the right care because its leverages existing resources in a new way to improve health outcomes in AAs with DM. AAs with DM are the right patients because many have poorly controlled DM, take suboptimal medications, and face treatment barriers, often social in nature. Now is the right time, as the population becomes more racially diverse, healthcare costs increase, and demand for safety, quality, and value intensify. In these ways DM I-TEAM is right for American healthcare, bringing us closer to Healthy People 2020's twin goals of reducing the personal and societal costs of DM, and achieving health equity for all.
DM I-TEAM takes a dynamic team approach to diabetes management whereby the primary care physician, the study pharmacist, the diabetes educator, and the CHW collaborate to build patient trust, encourage diabetes self-management, and optimize medication regimens. Each member of the team plays a pivotal role in identifying important information that prevents effective diabetes management, and then works together to provide multi-layered support to patients. The roles of each team member are as follows:
CHW: The CHW extends clinic-based care into participants' homes to strengthen patient/provider relationships, customize diabetes education, and develop tailored treatment plans. The CHW facilitates telemedicine visits with the PCP and diabetes educator to build trust in the health care system by increasing participants' access to their care team. The quality and content of these visits is enhanced by CHW-provided information about the participant's life situation (e.g., family circumstances, barriers to optimal diabetes self-management, home environment), and current self-management practices and beliefs. There will be 6 90 minute in-home CHW sessions within 3 months of randomization (telemedicine sessions will occur during 3 of these visits). Booster sessions will occur 5, 7, and 11 months after randomization. During these visits, the CHW will (1) reinforce the diabetes treatment plan articulated by the PCP, (2) gather information regarding barriers to diabetes self-management behaviors and communicate them to the team; (3) inform the team of the participant's health-related questions/issues; (4) provide culturally-relevant diabetes education using appropriate educational materials; (5) work with the participant to formulate and execute diabetes Action Plans using the principles of Behavioral Activation (BA); and (6) communicate the participant's progress with their Action Plans to the team. BA is a behavioral technique based on reinforcement theory that is used to help people overcome avoidant tendencies through goal setting, activity scheduling, and graded task assignment. BA was originally developed to treat depression. Our research has demonstrated that BA can successfully facilitate diabetes self-management. The DM I-TEAM treatment manual (which is already developed but will be refined during the study start-up phase) describes each session in detail, and includes scripts and didactics for the CHW interventionist. The manual is not included in this grant submission due to space limitations. At each session, the CHW educates participants to contact the ED (either by phone or by patient portal) prior to presenting for services. Participants are given "emergency kits" that contain glucometers and related supplies and glucose tablets. The ED physician may recommend that participant's test their glucose and treat hypoglycemia prior to or instead of reporting to the ED.
PCP: The PCP provides diabetes care as per standard practice, but care is supplemented with input from the pharmacist and the CHW, and with telemedicine visits. The PCP optimizes medication regimens based on pharmacist recommendations. As the course of treatment progresses, the PCP reinforces Action Plans with the participant during clinic visits.
Pharmacist: With information gathered by the CHW and from the participant's electronic medical records (EMR), the pharmacist performs a comprehensive evaluation of the participant's medications to identify medications that are contraindicated in older patients, are not being taken as prescribed, are being taken incorrectly, are improperly dosed, or may be causing undesirable side effects. Based on her assessment, the pharmacist may recommend that the PCP modify the current medication regimen.
Diabetes Educator: The diabetes educator provides telemedicine visits to supplement diabetes education provided by the CHW, answer participants' questions, and reinforce medication adherence.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Thomas Jefferson University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- African American race
- Age ≥ 35 years; When first proposed the age criterion was 60 or older; it was later modified to 35 and older
- Type 1 or 2 DM
- A DM-related cause for the ED visit (i.e., hyperglycemia/hypoglycemia, diabetic ketoacidosis, chest pain, skin or soft tissue infection, diabetic neuropathy, retinopathy, urinary tract infection/pyelonephritis/acute renal injury, requesting DM medication refill) OR an hemoglobin A1c of 7.0% or greater within the past 30 days
Exclusion Criteria:
- Evidence of cognitive and functional decline suggestive of dementia.
- Anti-dementia medication use
- Life expectancy less than one year (in the opinion of the evaluating ED physician)
- DSM-V psychiatric disorders other than anxiety or depression (as per EMR)
- Intoxicated
- Suicidal
- In police custody or currently incarcerated
- Undergoing medical clearance for a detox center or any involuntary court or magistrate order
- Lives in assisted living, currently in a rehabilitation facility (other than Jefferson), lives in a nursing home or skilled nursing facility
- Pregnant
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: DM I-TEAM
DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months.
During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs).
In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
|
DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months.
During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs).
In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
|
Žádný zásah: Usual Medical Care
Usual medical care
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Number of emergency room visits and hospitalizations over 12 months
Časové okno: 12 months
|
The primary efficacy analysis will consider the number of incident diabetes-related ED visits and/or hospitalizations (i.e., an "event") over 12 months after the index ED visit.
Each ED visit or hospitalization is counted as a single event (although an ED visit that leads to a hospitalization is counted once).
ED visits and hospitalization will be ascertained through chart reviews and subject self-report.
|
12 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
hemoglobin A1c
Časové okno: 12 months
|
Subjects will have their hemoglobin A1c tested using a point of care test.
|
12 months
|
Potentially Inappropriate Medications (PIMS)
Časové okno: 12 months
|
PIMS will be assessed via chart review by a clinical pharmacist.
|
12 months
|
Physician Trust
Časové okno: 12 months
|
Physician trust will be assessed with the Multidimensional Trust in Health Care Systems.
This 17-item scale measures trust in physicians (e.g., "I trust my doctor's judgment"); health payers (e.g., "Healthcare payers are good at what they do"); and health care institutions (e.g., "Healthcare institutions provide high quality care").
|
12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Barry Rovner, MD, Thomas Jefferson Uinversity
Publikace a užitečné odkazy
Obecné publikace
- Rovner BW, Casten RJ, Chang AM, Hollander JE, Rising K. Mistrust, Neighborhood Deprivation, and Telehealth Use in African Americans with Diabetes. Popul Health Manag. 2021 Dec;24(6):699-700. doi: 10.1089/pop.2021.0094. Epub 2021 May 17.
- Rovner BW, Casten RJ. Medication Beliefs and Depression in African Americans With Diabetes. Am J Geriatr Psychiatry. 2021 Dec;29(12):1296-1297. doi: 10.1016/j.jagp.2021.03.011. Epub 2021 Apr 9. No abstract available.
- Rovner BW, Casten RJ. Emergency department visits in African Americans with mild cognitive impairment and diabetes. J Diabetes Complications. 2021 May;35(5):107905. doi: 10.1016/j.jdiacomp.2021.107905. Epub 2021 Mar 16.
- Rovner BW, Casten RJ. Discordant health beliefs and telehealth use in African Americans with diabetes. J Am Geriatr Soc. 2021 Jun;69(6):1684-1686. doi: 10.1111/jgs.17081. Epub 2021 Mar 5. No abstract available.
- Rovner BW, Casten RJ, Chang AM, Hollander JE, Kelley M, Rising KL. Cognitive Deficits in African Americans With Diabetes in an Emergency Department. Am J Geriatr Psychiatry. 2020 Apr;28(4):503-504. doi: 10.1016/j.jagp.2019.07.018. Epub 2019 Aug 6. No abstract available.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 4100077081
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na DM I-TEAM
-
University of ManitobaUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); Laval UniversityNáborOmezení mobilityKanada
-
Seattle Children's HospitalUniversity of WashingtonAktivní, ne náborAutismus | Včasná intervenceSpojené státy
-
Jennifer B. LevinAmerican Heart AssociationAktivní, ne nábor
-
Boston University Charles River CampusWayne State UniversityDokončenoDětská mozková obrna | Intelektuální postižení | Vývojová postižení | Autismus | Mládež v přechodném věku
-
University of Colorado, DenverZápis na pozvánku
-
University of ManitobaJuvenile Diabetes Research Foundation; Canadian Institutes of Health Research...Zatím nenabírámeFyzická aktivita | Diabetes typu 1
-
University of RochesterDokončeno
-
Medical College of WisconsinNábor
-
VA Office of Research and DevelopmentMinneapolis Veterans Affairs Medical Center; Ralph H. Johnson VA Medical CenterZápis na pozvánkuUžívání tabáku | Mnohočetné plicní uzliny | Solitární plicní uzelSpojené státy
-
Desentum OyDokončenoAlergie na pyl břízyFinsko